TLR4 agonist. Promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. Acts as an adjuvant in vivo; enhances X-15 specific antibody serum concentrations, when administered with X-15-KLH in mice.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 2 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 691.78. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.45 mL||7.23 mL||14.46 mL|
|5 mM||0.29 mL||1.45 mL||2.89 mL|
|10 mM||0.14 mL||0.72 mL||1.45 mL|
|50 mM||0.03 mL||0.14 mL||0.29 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Li et al (2016) Intranasal vaccination against HIV-1 with adenoviral vector-based nanocomplex using synthetic TLR-4 agonist peptide as adjuvant. Mol.Pharm. 13 885 PMID: 26824411
Shanmugam et al (2012) Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PLoS One 7 e30839 PMID: 22363498
If you know of a relevant reference for RS 09, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: RS 09, supplier, RS09, TLR4, peptides, agonists, toll-like, receptors, agonism, adjuvants, Toll-like, Receptors, Tocris Bioscience
Citations for RS 09
Citations are publications that use Tocris products.
Currently there are no citations for RS 09. Do you know of a great paper that uses RS 09 from Tocris? If so please let us know.